Evommune shares tumble after EVO756 misses Phase 2b endpoints in atopic dermatitis trial

Evommune shares fell 16.4% in pre-market trading to $10.93 today after the Palo Alto, California-based clinical-stage biotech said after Tuesday’s close that EVO756, an oral MRGPRX2 antagonist in its pipeline, did not meet any primary or secondary endpoint at any dose in a Phase 2b randomized, double-blind, placebo-controlled trial. The study enrolled 121 adults with moderate-to-severe atopic dermatitis and lasted 12 weeks.

Evommune has decided not to proceed with EVO756 for atopic dermatitis, but it will continue Phase 2b development of the compound for migraine prophylaxis.

The decline carries extra significance because it represents EVO756’s second consecutive Phase 2b failure in 2026. The investigational therapy had previously fallen short of its primary endpoint in a chronic spontaneous urticaria (CSU) trial earlier this year, prompting Evommune to completely halt that program.

With the atopic dermatitis program set aside, the near-term value of the pipeline increasingly depends on EVO301, an IL-18 binding protein fusion candidate in Phase 2b development for atopic dermatitis and ulcerative colitis, and on the newly initiated Phase 2b study of EVO756 for migraine prophylaxis.

Evercore ISI reportedly reiterated its Buy rating on Evommune today, while analyst views overall have been sharply mixed in recent weeks.

The broader U.S. equity market did not act as a cushion, with all three major indices in the red during pre-market trading.

The S&P 500 fell 0.2%, the Dow Jones Industrial Average dropped 0.3%, and the Nasdaq was 0.5% lower, as investors dealt with a cautious macro backdrop marked by higher oil prices due to U.S.-Iran tensions, elevated Treasury yields, and anticipation of key inflation data — CPI and PPI — due later this week.

The combination of a failed binary clinical readout in a closely watched indication, the earlier CSU disappointment, and a broadly risk-off environment piled pressure on EVMN shares, pushing the stock toward its 52-week low of $10.47 and erasing most of the gains it had made since the previous pipeline setback.

This article was produced with the assistance of artificial intelligence and reviewed by an editor. Further information is available in our Terms & Conditions.